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Introduction: We previously reported that progression-free survival 
(PFS) may be a candidate surrogate end point for overall survival 
(OS) in first-line extensive-stage small-cell lung cancer (ES-SCLC) 
using data from three randomized trials (Foster, Cancer 2011). In this 
validation study (N0424-Alliance), we assessed the patient-level and 
trial-level surrogacy of PFS using data from seven new first-line phase 
II/III ES-SCLC trials and across all 10 trials as well (seven new, three 
previous).
Methods: Individual patient data were utilized across the seven new 
trials (2259 patients) and all 10 trials (2855 patients). Patient-level 
surrogacy (Kendall’s τ) was assessed using the Clayton copula bivari-
ate survival model. Trial-level surrogacy was assessed through asso-
ciation of the log hazard ratios on OS and PFS across trials, including 
weighted (by trial size) least squares regression (WLS R2) of Cox 
model effects and correlation of the copula effects (copula R2). The 
minimum effect on the surrogate (MES) needed to detect a nonzero 
treatment effect on OS was also calculated.
Results: The median OS and PFS across all 10 trials were 9.8 and 5.9 
months, respectively. PFS showed strong surrogacy within the 7 new 
trials (copula R2 = 0.90 [standard error = 0.27], WLS R2 = 0.83 [95% 
confidence interval: 0.43, 0.95]; MES = 0.67, and Kendall’s τ = 0.58) 
and across all 10 trials (copula R2 = 0.81 [standard errors = 0.25], 
WLS R2 = 0.77 [95% confidence interval: 0.47–0.91], MES = 0.70, 
and Kendall’s τ = 0.57).
Conclusions: PFS demonstrated strong surrogacy for OS in first-
line ES-SCLC based on this external validation study of individual 
patient data. PFS is a good alternative end point to OS and should be 
considered when resource constraints (time or patient) might make it 
useful or desirable in place of OS. Additional analyses are needed to 
assess its appropriateness for targeted agents in this disease setting.
Key Words: Extensive-stage small-cell lung cancer, Surrogate end-
points, Pooled analysis, Progression-free survival, Overall survival.
(J Thorac Oncol. 2015;10: 1099–1106)
Lung cancer is expected to cause 159,260 deaths within the United States in 2014.1 Approximately 15% of lung cancer 
patients have small-cell lung cancer (SCLC),2 and approxi-
mately 70% of patients with SCLC have extensive-stage dis-
ease (ES-SCLC).2 For patients with ES-SCLC, the current 
standard treatment in the first-line setting is etoposide and 
platinum,3–6 which generally yields a median overall survival 
(OS) in the range of 8–12 months. Unfortunately, few dramatic 
improvements in ES-SCLC therapy have been made in the past 
20 years,7 leading to a situation where a shorter term, surrogate 
end point could make testing future therapies more efficient.
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OS remains the most relevant clinical end point within 
oncology clinical trials, including ES-SCLC. Because the 
median OS for ES-SCLC patients is relatively short, one 
may wonder why it would be important to find a valid sur-
rogate end point for OS in this disease. The reasons that 
a valid surrogate end point may still be important in this 
setting include the fact that a valid surrogate would allow 
a shorter follow-up time requirement for clinical trials of 
new agents, and the potential that effective subsequent ther-
apies, such as topotecan,8 may make it difficult to assess 
the true treatment effect of an agent in the first-line setting. 
Moreover, many phase II trials in SCLC continue to use 
response rate as the primary end point, with no supporting 
evidence of its association to true clinical benefit.9 A sur-
rogate end point is one that can substitute for a true clinical 
end point and can predict patient outcome sooner than with 
the true end point.10,11 To demonstrate that an end point is 
a valid surrogate, it must meet two criteria. First, the sur-
rogate end point must be associated with the true clinical 
end point (patient-level surrogacy), and second, the treat-
ment effects on the surrogate end point must be strongly 
associated with the treatment effects on the true end point 
(trial-level surrogacy).10,11 If both of these criteria are met, it 
can be argued that the surrogate end point is valid and can 
be used in place of the true end point.
A PubMed literature search for trials reported over a 
10-year period (2005–2014) in first-line ES-SCLC in the phase 
II setting showed that only 8 of the 46 published trials used pro-
gression-free survival (PFS) as the primary end point, with OS 
being used even less often (7 of 46 trials). Nearly all phase II 
studies over this period used response as the primary end point 
(30 of 46). Even in the randomized Phase II setting, response 
was used more often than PFS, where 7 of the 10 randomized 
Phase II studies used response as the primary end point and 
only 2 used PFS. We previously reported that PFS may be a can-
didate surrogate end point for OS in first-line ES-SCLC using 
data from three randomized North Central Cancer Treatment 
Group (NCCTG) trials (2, phase III; 1, phase II).9 This prior 
study also demonstrated that PFS is a better predictor of OS 
than tumor response;9 however, PFS is still not routinely used as 
the primary end point in the phase II setting in ES-SCLC.
PFS is defined as the time from study registration or ran-
domization to the first of either disease progression or death 
from any cause. Issues with PFS as an end point are well 
documented and discussed elsewhere.12–18 Despite the many 
issues with PFS, it is considered a possible surrogate end point 
for OS, as it is unaffected by subsequent therapies and could 
shorten the time to drug approval. Given preliminary promis-
ing evidence of PFS as a candidate surrogate end point for OS, 
we sought to formally assess the patient-level and trial-level 
surrogacy of PFS using data from seven additional first-line 
randomized phase II/III trials (2259 patients). For this analysis, 
individual patient data from the seven new trials and 10 total 
trials (including the three previous trials) were utilized, which 
included eight phase III and two phase II studies. These 10 tri-
als (2855 patients) consisted of a series of published first-line 
randomized phase II/III studies conducted by the NCI-funded 
cooperative groups or JCOG since 1982, which represents the 
largest individual patient data analysis in this disease setting 
that includes multicenter cooperative group trials conducted 
within the United States, Canada, and Japan.
MATERIALS AND METHODS
Data and Trial Characteristics
Individual patient data were utilized from the seven 
new non-NCCTG trials (2259 patients) and all 10 randomized 
ES-SCLC first-line therapy trials that accrued 2855 patients 
between 1982 and 2007 (Table 1). 
This included eight phase III studies and two phase II 
studies. The radiographic scanning interval was similar across 
all studies, where it was generally from 3 to 6 weeks during 
treatment. One trial had four treatment arms, thus 12 total two-
arm comparisons were made. OS was the primary end point in 
all phase III trials. For the phase II studies, the primary end point 
was 1-year OS rate (CALGB 30103) or response rate (NCCTG 
932053), with none powered for OS (i.e., time-to-death). The 
randomized phase II studies were included because of the low 
number of available randomized trials in this disease setting. 
Three phase III trials and one randomized phase II trial showed 
a significant OS benefit for the experimental treatment versus 
the control treatment (National Cancer Institute of Canada 
Clinical Trials Group [NCIC CTG] BR4, JCOG 9511, NCCTG 
862051, NCCTG 932053; Table 2). In addition, one trial dem-
onstrated significantly worse OS for the experimental treatment 
versus the control treatment (CALGB 30103; Table 2).
Institutional Review Boards at the study sites had previ-
ously approved these trials, and all participants provided writ-
ten informed consent. This analysis was conducted under an 
IRB approved protocol (N0424-Alliance). See Table 1 for a 
detailed listing of the individual trial characteristics, where the 
three NCCTG trials were reported previously.9
Statistical Methods
This study assessed the association between PFS and OS 
at both the patient-level and trial-level. First, we assessed the 
patient-level and trial-level surrogacy of PFS using data from 
seven new first-line phase II/III ES-SCLC trials to externally 
validate our previous findings. Subsequently, the patient-level 
and trial-level surrogacy was also assessed across all 10 trials 
(including the data from the three previously reported trials). 
PFS was defined as the time from randomization to the first 
of either disease progression or death from any cause, where 
the progression status was typically based on preresponse 
evaluation criteria in solid tumors (pre-RECIST; 8 of 10 trials). 
Because we did not have the raw tumor measurement data across 
all studies, we were unable to convert the progression status into 
one specific criterion (RECIST vs. pre-RECIST). For this anal-
ysis, therefore, we used the progression status information that 
was collected and reported for each trial. OS was defined as the 
time from randomization to death from any cause.
Patient-level surrogacy was assessed using a bivariate 
survival model constructed from a Clayton copula with Weibull 
marginal distributions, as developed by Burzykowski et al.10 and 
updated by Renfro et al.29 Specifically, the copula association 
parameter (assumed equal across trials) was transformed onto 
the scale of Kendall’s τ ∈ [-1, 1], where a value of τ equal to 
1 would indicate a perfect positive association between OS 
Copyright © 2015 by the International Association for the Study of Lung Cancer
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and PFS, and values above 0.50 demonstrate a strong positive 
association between OS and PFS at the individual patient level. 
Trial-level surrogacy was assessed through association of the 
log hazard ratios (HRs) on OS and PFS across trials, includ-
ing weighted (by trial size) least squares regression (WLS R2) 
of marginal Cox model effects30,31 and weighted (by trial size) 
correlation of the joint copula effects (copula R2 and associated 
standard errors [SE]).10,29 Both the WLS R2 and the copula R2 
values range from 0 to 1, with values close to 0 suggesting poor 
surrogacy and values close to 1 indicating strong surrogacy. 
Generally, strong trial-level surrogacy is demonstrated with R2 
values of approximately 0.80 or higher as shown in prior stud-
ies within colorectal cancer, ovarian cancer, and non–small-cell 
lung cancer (NSCLC).32 In addition, a surrogacy assessment was 
also conducted based on the leave-one-out prediction of the true 
end point effect (OS) given the surrogate effect (PFS) from the 
other trials. Specifically, the percentage of trials for which the 
observed treatment effect (HR) on OS fell within its predicted 
95% confidence interval (CI) was calculated, based on PFS.
We also calculated the minimum treatment effect on PFS 
(surrogate) needed to predict a statistically significant improve-
ment on OS (true end point), called the minimum effect on the 
surrogate (MES). This was calculated by using an unweighted 
least squares regression model for the Cox model treatment 
effects (log HRs for PFS and OS from each trial), where the PFS 
treatment effects were used to predict the OS treatment effects on 
the log scale. For this calculation, we assumed a future trial with 
a size equal to the median of our trial sizes (n = 187) and found 
the smallest effect on PFS corresponding to a 95% prediction 
interval for OS that excluded 0 on the negative side (e.g., upper 
limit of interval on the log HR scale <0). The MES results are 
reported on the HR scale. Statistical analyses were performed by 
Alliance statisticians using SAS v9.2 (SAS Institute, Cary, NC) 
and R v3.0.2 software (R Foundation for Statistical Computing), 
where the data were locked for analysis on September 30, 2013.
RESULTS
Patient Characteristics and Outcomes
Data included a total of 2855 first-line treated patients with 
ES-SCLC across all 10 trials (2259 patients from seven new tri-
als and 596 from three previous trials). The median age was 62 
years (range, 22–86). Sixty-two percent were male, and 87% had 
a performance status of 0 or 1. The median follow-up for the 
94 patients still alive was 40.2 months (range, 0.3–143.8). The 
overall median OS and PFS were 9.8 months (95% CI, 9.6–10.1) 
TABLE 2.  Leave-one-out Surrogacy Assessmenta
Left Out Trial Phase
Primary  
End point
Significantly Positive 
for Primary End 
point (Based on 
Published Findings)
Observed HR  
(PFS, Experimental 
vs. Control)  
(95% CI)
Observed HR  
(OS, Experimental 
vs. Control)  
(95% CI)
Cox model  
Predicted HR (OS) 
(95% CI)b,c
7 new trials
  CALGB 30103 II 1-year OS Nod 1.93 (1.02, 3.64) 2.14 (1.12, 4.09) 1.93 (1.15, 3.23)
  CALGB 9732 III OS No 0.96 (0.81, 1.13) 0.94 (0.79, 1.11) 0.97 (0.87, 1.09)
  CALGB 9033 III OS No 0.85 (0.67, 1.06) 0.90 (0.72, 1.13) 0.84 (0.76, 0.94)
  NCIC CTG BR4 III OS Yes 0.56 (0.44, 0.71) 0.72 (0.57, 0.91) 
0.90 (0.69, 1.18)
0.49 (0.41, 0.57)
  NCIC CTG BR8 III OS No 0.92 (0.70, 1.20) 0.94 (0.81, 1.10) 0.93 (0.83, 1.03)
  SWOG S0124 III OS No 0.90 (0.77, 1.05) 0.60 (0.43, 0.83) 0.91 (0.81, 1.01)
  JCOG 9511 III OS Yes 0.65 (0.47, 0.90) 0.65 (0.55, 0.76)
3 Previous trials
  NCCTG 862051 III OS
  Arm A vs. B Yese 0.77 (0.55, 1.06) 0.74 (0.53, 1.02) 0.76 (0.68, 0.86)
  Arm C vs. B Not reportedf 0.79 (0.57, 1.10) 0.73 (0.53, 1.01) 0.80 (0.71, 0.89)
  Arm D vs. B Not reportedg 0.87 (0.64, 1.20) 0.99 (0.72, 1.36) 0.87 (0.78, 0.97)
  NCCTG 892051 III OS No 1.13 (0.87, 1.46) 1.20 (0.92, 1.55) 1.15 (0.99, 1.33)
  NCCTG 932053 II Responseh Yesh 0.72 (0.41, 1.25) 0.51 (0.29, 0.90)h 0.74 (0.68, 0.81)
aBolded prediction intervals did not contain observed OS HR.
bUnweighted Cox model approach showed that 9 of 12 (75%) comparisons were accurately predicted.
cPrediction method used other n − 1 comparisons.
dThis study showed a significantly negative result, where the experimental treatment had significantly worsened OS and PFS when compared with the control treatment.
eThe original publication reported that arm A was significantly improved when compared with Arm B for OS (p = 0.04), but using more mature follow-up data showed only a 
borderline significant result in our study (p = 0.06). The result was still very similar overall.
f The original publication did not specifically report this finding, but the Kaplan–Meier analyses showed that Arms C and A had overlapping OS curves, which would support that 
arms C and A were similar, and that arm C most likely had significantly improved OS when compared with Arm B. Our finding supports at least a borderline significant result (p = 0.06).
gThe original publication did not specifically report this finding, but the Kaplan–Meier analyses showed that Arms D and B had overlapping OS curves. They were clearly 
nonsignificant based on the graph.
hThe original publication did not report the HRs or p values for the OS/PFS findings, but our data clearly show that OS was significantly improved in the experimental arm (vs. 
control) with a p value of 0.02.
PFS, progression-free survival; OS, overall survival; HR: hazard ratio; CI: confidence interval, SWOG, Southwest Oncology Group; JCOG, Japan Clinical Oncology Group; 
CALGB, cancer and leukemia group B
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and 5.9 months (95% CI, 5.8–6.1), respectively. Experimental 
treatments did slightly better overall when compared with con-
trol treatments for both OS and PFS (Fig. 1). Of the 2803 PFS 
events, there were 2287 disease progressions (82%) and 516 
deaths without progression (18%). The median time from pro-
gression to death was 3.9 months (95% CI: 3.6–4.1).
Surrogacy Results
External validation using seven new trials
Across the seven new trials, trial-level surrogacy results 
were strong, with copula R2 = 0.90 (SE = 0.27) and WLS 
R2 = 0.83 (95% CI: 0.43, 0.95; Fig. 2), with strong levels of 
patient-level surrogacy as well (Kendall’s τ = 0.57). The MES 
HR across all new trials was 0.67, which indicates that the PFS 
HR would need to be 0.67 or less in favor of the experimental 
treatment to show a potential benefit for OS. These seven new 
trials all included a platinum/etoposide treatment combination 
in the first-line setting.
Overall results
Across all 10 trials, trial-level surrogacy measures were 
strong, with copula R2 = 0.81 (SE = 0.25) and WLS R2 = 0.77 
(95% CI: 0.47, 0.91; Fig. 3), with strong levels of patient-level 
surrogacy as well (Kendall’s τ = 0.57). The MES HR across all 
trials was 0.70, which indicates that the PFS HR would need to 
be 0.70 or less in favor of the experimental treatment to show 
a potential benefit for OS. Strong surrogacy results were also 
obtained when assessing the nine first-line studies that included 
a platinum/etoposide treatment combination (copula R2 = 0.87 
[SE = 0.22], WLS R2 = 0.82 [95% CI: 0.49, 0.92], MES = 0.75, 
and Kendall’s τ = 0.58; Fig. 4) or when assessing the eight phase 
III trials only (copula R2 = 0.78 [SE = 0.30], WLS R2 = 0.76 
[95% CI: 0.37, 0.91], MES = 0.73, and Kendall’s τ = 0.58).
FIGURE 1.  Kaplan–Meier curves for overall survival 
(OS) and progression-free survival (PFS) by experi-
mental versus control treated patients (N = 2855).
FIGURE 2.  Plot of the log of the hazard ratios for each 
experimental arm versus control arm for each trial for the end 
points of progression-free survival (PFS) and overall survival 
(OS) across the seven new trials.
FIGURE 3.  Plot of the log of the hazard ratios for each 
experimental arm versus control arm for each trial for the end 
points of progression-free survival (PFS) and overall survival 
(OS) across all 10 trials.
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The surrogacy assessment, across all 10 trials, using 
a leave-one-out prediction of each trial’s actual HR for OS 
based on its observed HR for PFS and joint effects from the 
other trials yielded a 67% prediction rate for the copula-based 
approach and a 75% prediction rate for the Cox model based 
approach, where 9 of the 12 experimental versus control arm 
comparisons were accurately predicted (i.e., prediction inter-
vals contained the observed HR for OS) based on the other 
n − 1 comparisons (Table 2). Out of the three outlier cases 
for which the predicted HR intervals failed to contain the 
observed OS HR, one was significant for both OS and PFS 
and had a predicted OS HR (95% CI) that was significant 
as well (NCIC CTG BR4). The other two outlier cases had 
observed OS HR confidence limits that overlapped with the 
predicted OS HR intervals (Table 2).
DISCUSSION
In this external validation study, PFS was assessed as 
a formal surrogate end point for OS across the 7 new trials 
(2259 patients) and across all 10 trials as well (2855 patients). 
Surrogacy was measured at both the patient and trial levels. 
Strong trial-level surrogacy results were obtained when assess-
ing the seven new trials only (copula R2 = 0.90 [SE = 0.27] and 
WLS R2 = 0.83), which provided an external validation of our 
previously reported analysis of the three NCCTG studies only 
(copula R2 = 0.80).9 Because the results of the seven new and 
three previous trials were similar, we also pooled the individ-
ual patient data across all 10 trials as well. Across all 10 trials, 
trial-level surrogacy measures were strong (copula R2 = 0.81 
[SE = 0.25] and WLS R2 = 0.77) and yielded similar results 
when considering the nine first-line studies that included a 
platinum/etoposide treatment combination (copula R2 = 0.87 
[SE = 0.22] and WLS R2 = 0.82) or when considering the eight 
phase III trials only (copula R2 = 0.78 [SE = 0.30] and WLS 
R2 = 0.76). Patient-level surrogacy measures were weaker 
(Kendall’s τ ranged from 0.57 to 0.58) but still showed that 
the correlation between OS and PFS was actually quite strong 
at the individual patient level, indicating that OS and PFS are 
definitely positively related.
Surrogacy analyses of PFS versus OS have been per-
formed across many disease sites with mixed results.14 PFS 
has been shown to be a valid surrogate end point for OS in 
advanced ovarian and advanced colorectal cancer.10,33–35 Other 
disease sites, including advanced breast cancer,36–39 advanced 
prostate cancer,40,41 advanced gastric cancer,42 and advanced 
NSCLC,43 have not supported PFS as a surrogate end point 
for OS. Within NSCLC, PFS has been assessed as a possible 
surrogate end point for OS with conflicting conclusions. One 
study reported that PFS may be an acceptable surrogate for 
OS in future trials in advanced NSCLC. In this pooled analy-
sis study of 2838 patients from seven randomized trials, the 
copula R2 was 0.83.44 In another meta-analysis study of 2334 
NSCLC patients from five randomized trials, only moderate 
surrogacy was found with a copula R2 of 0.62.45
In this study, the survival postprogression was short 
with a median of only 3.9 months, and the trial-level surro-
gacy was found to be strong (copula R2 = 0.90 [seven new tri-
als]; copula R2 = 0.81 [all 10 trials]). This result is in-line with 
prior research that has shown that the level of surrogacy tends 
to be related to the survival postprogression.46 For diseases 
with longer survival times postprogression, the surrogacy 
tends to be lower (e.g., breast cancer), whereas for diseases 
with shorter survival times postprogression (e.g., colon cancer 
before the availability of effective multiagent therapy) the sur-
rogacy tends to be stronger.
Within the randomized phase II setting, PFS is definitely 
appropriate to use as the primary end point in first-line ES-SCLC 
for two major reasons: (1) PFS has been shown to be a better pre-
dictor of OS compared with tumor response within ES-SCLC9 
and (2) most randomized phase II trials are powered to detect a 
large treatment effect (i.e., HR ≤ 0.70), which is similar to the 
MES values we observed in this study (MES = 0.67 [seven new 
trials] and MES = 0.70 [all 10 trials]). The MES of 0.70 from this 
pooled analysis demonstrates that if the observed PFS HR for a 
study was found to be 0.70 or less in favor of the experimental 
treatment (vs. control), PFS would still potentially predict for a 
significant improvement in OS for the experimental treatment. 
If a strong PFS effect is observed in the phase II setting (HR ≤ 
0.70), it would provide the study team with confidence to launch 
a larger phase III study with OS or PFS as the primary end point.
Despite the many strengths of this study, there are some 
limitations as well. First, most of the studies included were 
pre-RECIST (8 of the 10). Second, this study only included 
a series of 10 (seven new and three previous) published first-
line trials. As such, the confidence intervals around the sur-
rogacy estimates are wide, leaving uncertainty about the true 
surrogacy effect. We also stress that the trials included in this 
analysis, although many, are not comprehensive of all trials 
performed in this disease to date, and that they represent a 
nonrandom subset of trials. As the data become available from 
trials utilizing newer agents and targeted therapeutics, further 
FIGURE 4.  Plot of the log of the hazard ratios for each 
experimental arm versus control arm for each trial for the end 
points of progression-free survival (PFS) and overall survival 
(OS) within the nine first-line studies that included a plati-
num/etoposide treatment combination.
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analysis is warranted for assessing the validity of PFS as a 
surrogate for OS in that setting. Third, we acknowledge that 
including trials that enrolled patients from 1982 until 2007 
is a weakness in the analysis because of changes in workup 
methods and response assessment recommendations. We note, 
however, that 8 of the 10 included trials used the same crite-
ria for assessment of progression (pre-RECIST), whereas the 
other two trials used RECIST criteria (CALGB 30103, SWOG 
S0124). In addition, this time period has shown modest gains 
in OS mainly because of improvements in supportive care, the 
use of PCI, and changes in imaging modalities (stage migra-
tion).47 Finally, this study only included older trials that gen-
erally used platinum/etoposide treatment combinations (all 
seven new and two of three previous). The surrogacy results 
may differ when newer treatment regimens are shown to be 
more effective than platinum/etoposide.
In conclusion, PFS demonstrated strong potential sur-
rogacy for OS in first-line ES-SCLC based on this individual 
patient data analysis, which represents the largest surrogacy 
analysis ever in this disease population. This study supports 
PFS as a potential alternative to OS as the primary end point 
in randomized trials that use platinum/etoposide regimens 
in first-line ES-SCLC, especially when resource constraints 
(time or patient) might make PFS more useful or desirable 
in place of OS. Given the limited difference between median 
PFS and OS in this setting (approximately 4 months), OS may 
still be preferred, especially in the phase III setting. Additional 
analyses are needed to assess appropriateness of PFS as a sur-
rogate end point for targeted agents in this disease setting.
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